Patents by Inventor Shuichi Furuya
Shuichi Furuya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10940210Abstract: The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.Type: GrantFiled: September 10, 2020Date of Patent: March 9, 2021Assignee: National University Corporation Okayama UniversityInventors: Hideki Matsui, Shuichi Furuya, Hiroyuki Michiue, Hiroki Kakuta, Yasuaki Takeuchi
-
Patent number: 10894088Abstract: The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.Type: GrantFiled: November 24, 2017Date of Patent: January 19, 2021Assignee: National University Corporation Okayama UniversityInventors: Hideki Matsui, Shuichi Furuya, Hiroyuki Michiue, Hiroki Kakuta, Yasuaki Takeuchi
-
Publication number: 20200397910Abstract: The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.Type: ApplicationFiled: September 10, 2020Publication date: December 24, 2020Applicant: National University Corporation Okayama UniversityInventors: HIDEKI MATSUI, Shuichi Furuya, Hiroyuki Michiue, Hiroki Kakuta, Yasuaki Takeuchi
-
Publication number: 20200121800Abstract: The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.Type: ApplicationFiled: November 24, 2017Publication date: April 23, 2020Applicant: National University Corporation Okayama UniversityInventors: Hideki MATSUI, Shuichi FURUYA, Hiroyuki MICHIUE, Hiroki KAKUTA, Yusuaki TAKEUCHI
-
Publication number: 20100286063Abstract: In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby.Type: ApplicationFiled: May 7, 2010Publication date: November 11, 2010Inventors: Shuichi Furuya, Masami Kusaka
-
Patent number: 7622479Abstract: The present invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by formula: (wherein, R1b is a C6-10 aryl group which has substituent(s), and the like; Ta is a single bond, a C1-6 alkyl group, —CH2O—, and the like; X and Y are the same or different, and each is a nitrogen atom which may have substituent(s), and the like; the broken line is a single bond or a double bond; Za is a nitrogen atom or CH; W is a single bond, an oxygen atom, and the like; Q is a C6-10 aryl group which may have substituent(s) or an aromatic heterocyclic group which may have substituent(s)); or a salt thereof and a pharmaceutical composition comprising thereof.Type: GrantFiled: November 25, 2002Date of Patent: November 24, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Tsuneo Oda, Takashi Imada, Kenichiro Naito, Toshiya Tamura, Shuichi Furuya
-
Patent number: 7569570Abstract: The present invention provides a thienopyrimidine compound, represented by the formula [wherein, R1 is C1-4 alkyl, R2 is (1) phenyl optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino, or (2) a heterocyclic group optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino and the like, R3 is a hydrogen atom or C1-4 alkyl, R4 is C1-4 alkyl optionally having a substituent such as C1-4 alkoxy-carbonyl, carboxyl, mono C1-4 alkylamino and N—C1-4 alkyl-N—C7-10 aralkylamino and the like] or a salt thereof, which has antagonistic action for gonadotropin-releasing hormone.Type: GrantFiled: January 29, 2003Date of Patent: August 4, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Shuichi Furuya, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
-
Publication number: 20090169610Abstract: The present invention provides cancer treatment preparations of excellent targetability. The sugar chain-modified liposomes of the present invention, which contain an aromatase inhibitor, anti-androgenic agent, lyase inhibitor, GnRH agonist, GnRH antagonist, anti-angiogenic agent, tyrosine kinase inhibitor, serine-threonine kinase inhibitor, antibody having an anticancer activity, ansamitocin, capecitabine, celmoleukin, docetaxel hydrate, gemcitabine hydrochloride, oxaliplatin, prednisolone, tegafur-uracil mixtures, zinostatin stimalamer or arsenic trioxide may be used as cancer treatment preparations having an excellent targetability.Type: ApplicationFiled: February 2, 2007Publication date: July 2, 2009Inventors: Noboru Yamazaki, Sei Yoshida, Masuo Yamaoka, Akira Hori, Shigeya Kakimoto, Shuichi Furuya
-
Publication number: 20090048273Abstract: The present invention provides a premature ovulation inhibitor for use in in vitro fertilization or embryo transfer process, which contains a nonpeptidic compound having a gonadotropin releasing hormone antagonistic action. The premature ovulation inhibitor for use in in vitro fertilization or embryo transfer process of the present invention is low toxic, permits oral administration, and has a superior inhibitory effect on premature ovulation in in vitro fertilization or embryo transfer process.Type: ApplicationFiled: July 21, 2006Publication date: February 19, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Shuichi Furuya, Masami Kusaka
-
Publication number: 20070179097Abstract: In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby.Type: ApplicationFiled: March 27, 2007Publication date: August 2, 2007Inventors: Shuichi Furuya, Masami Kusaka
-
Publication number: 20050250793Abstract: It is intended to provide a preventing or treating agent for hot flash which comprises a nonpeptidic compound having gonadotropin releasing hormone antagonistic activity, in particular, a preventing or treating agent for hot flash which comprises a nonpeptidic compound having gonadotropin releasing hormone antagonistic activity, wherein said compound is capable of entering the brain.Type: ApplicationFiled: April 10, 2003Publication date: November 10, 2005Inventors: Masami Kusaka, Shuichi Furuya
-
Patent number: 6962919Abstract: A compound of the formula: wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R1, R2 and R3 each is (i) H or (ii) a group bound via C, N, O or S; R4 is a group bound via C; R5 is H or a group bound via C or O; R6 is H or a group bound via C; R7 is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.Type: GrantFiled: January 11, 2002Date of Patent: November 8, 2005Assignee: Takeda Pharmaceutical Co., Ltd.Inventors: Shuichi Furuya, Toshihiro Imaeda, Satoshi Sasaki
-
Publication number: 20050222174Abstract: The present invention provides a thienopyrimidine compound, represented by the formula [wherein, R1 is C1-4 alkyl, R2 is (1) phenyl optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino, or (2) a heterocyclic group optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino and the like, R3 is a hydrogen atom or C1-4 alkyl, R4 is C1-4 alkyl optionally having a substituent such as C1-4 alkoxy-carbonyl, carboxyl, mono C1-4 alkylamino and N—C1-4 alkyl-N—C7-10 aralkylamino and the like] or a salt thereof, which has antagonistic action for gonadotropin-releasing hormone.Type: ApplicationFiled: January 29, 2003Publication date: October 6, 2005Applicant: Takeda Chemical Industries Ltd.Inventors: Shuichi Furuya, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
-
Publication number: 20050215528Abstract: In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby.Type: ApplicationFiled: August 8, 2002Publication date: September 29, 2005Inventors: Shuichi Furuya, Masami Kusaka
-
Publication number: 20050101647Abstract: The present invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by formula: (wherein, R1b is a C6-10 aryl group which has substituent(s), and the like; Ta is a single bond, a C1-6 alkyl group, —CH2O—, and the like; X and Y are the same or different, and each is a nitrogen atom which may have substituent(s), and the like; the broken line is a single bond or a double bond; Za is a nitrogen atom or CH; W is a single bond, an oxygen atom, and the like; Q is a C6-10 aryl group which may have substituent(s) or an aromatic heterocyclic group which may have substituent(s)); or a salt thereof and a pharmaceutical composition comprising thereof.Type: ApplicationFiled: November 25, 2002Publication date: May 12, 2005Inventors: Tsuneo Oda, Takashi Imada, Kenichiro Naito, Toshiya Tamura, Shuichi Furuya
-
Publication number: 20050101657Abstract: The present invention provides an androgen receptor antagonistic agent and a superior prophylactic or therapeutic agent for hormone-sensitive cancer, which contain a compound of the formula: wherein, R1 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R2 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R3 is a hydrogen atom, a hydrocarbon group which may have substituent(s), an acyl group or a heterocyclic group which may have substituent(s), R4 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, and R5 is a cyclic group which may have substituent(s); or a salt thereof, or its prodrug.Type: ApplicationFiled: December 26, 2002Publication date: May 12, 2005Applicant: Takeda Chemical Industries Ltd.Inventors: Shuichi Furuya, Nobuyuki Matsunaga, Masami Kusaka, Takahito Hara, Junichi Miyazaki
-
Publication number: 20040138160Abstract: This invention provides a prophylactic or therapeutic method for cancer.Type: ApplicationFiled: March 2, 2004Publication date: July 15, 2004Inventors: Kenichiro Naito, Shuichi Furuya, Akihiro Tasaka, Toshikazu Ban
-
Publication number: 20040116330Abstract: A method of controlling the growth and differentiation of cancer is provided.Type: ApplicationFiled: February 5, 2004Publication date: June 17, 2004Inventors: Kenichiro Naito, Shuichi Furuya, Akihiro Tasaka, Toshikazu Ban
-
Publication number: 20030134863Abstract: The present invention provides an agent for the prophylaxis or treatment of Alzheimer's disease. The agent for the prophylaxis or treatment of Alzheimer's disease of the present invention containing a compound having a GnRH antagonistic action shows low toxicity and has a superior preventive and therapeutic effect on Alzheimer's disease.Type: ApplicationFiled: October 3, 2002Publication date: July 17, 2003Inventors: Shuichi Furuya, Nobuhiro Suzuki
-
Patent number: 6514988Abstract: A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, pplycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g.Type: GrantFiled: September 29, 2000Date of Patent: February 4, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Shuichi Furuya, Nobuo Choh, Koichi Kato, Shuji Hinuma